Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $18.3 million.

  • Lyell Immunopharma's Shares Outstanding (Diluted Average) rose 42.55% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 42.55%. This contributed to the annual value of $261.5 million for FY2024, which is 4.18% up from last year.
  • As of Q3 2025, Lyell Immunopharma's Shares Outstanding (Diluted Average) stood at $18.3 million, which was up 23.49% from $14.8 million recorded in Q2 2025.
  • Lyell Immunopharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $295.1 million during Q1 2025, with a 5-year trough of $12.8 million in Q2 2024.
  • For the 3-year period, Lyell Immunopharma's Shares Outstanding (Diluted Average) averaged around $170.1 million, with its median value being $250.2 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 1,313.72% in 2022, then tumbled by 94.90% in 2024.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Shares Outstanding (Diluted Average) stood at $135.9 million in 2021, then surged by 81.79% to $247.1 million in 2022, then climbed by 1.58% to $251.0 million in 2023, then grew by 4.18% to $261.5 million in 2024, then soared by 42.55% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, $14.8 million for Q2 2025, and $295.1 million during Q1 2025.